Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.

There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in myocardial infarction. However, few studies have explored the effects and optimal concentration of tirofibans in diminishing the extent of myocardial reperfusion injury (RI).Rats received 120 minutes of coronary ligation and 180 minutes of reperfusion. The rats were then divided into 7 groups based on the concentration of tirofiban administered intravenously 30 minutes prior to coronary reperfusion to the end of reperfusion. The ratio of myocardial necrotic area to area at risk (AAR), and myocardial malondialdehyde (MDA) and plasma myeloperoxidase (MPO) activities were measured. The apoptotic index (AI) was the percentage of myocytes positive for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) out of all myocytes stained by 4', 6-diamidino-2-phenylindole (DAPI).The ratio of myocardial necrotic area to AAR significantly decreased in all tirofiban subgroups. The MDA activity for tirofiban concentrations of 2 and 5 ug/kg/minute showed a slight reduction. MPO activity was significantly decreased at a tirofiban concentration of 2 ug/kg/minute. The AI was significantly decreased at a tirofiban concentration of ≥ 0.4 ug/kg/minute.The results indicate that a tirofiban can significantly ameliorate the cardiac RI and myocyte apoptosis in rats.

[1]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[2]  Yan Cai,et al.  Activation of Akt/GSK-3β signaling pathway is involved in intermedin1–53 protection against myocardial apoptosis induced by ischemia/reperfusion , 2009, Apoptosis.

[3]  S. Lecour.  Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? , 2009, Journal of molecular and cellular cardiology.

[4]  R. Pi,et al.  Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. , 2007, European journal of pharmacology.

[5]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[6]  E. Romagnoli,et al.  Rationale for intracoronary administration of abciximab , 2007, Journal of Thrombosis and Thrombolysis.

[7]  Ajai Kumar Jain,et al.  PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .

[8]  Yaqin Xu,et al.  Activated platelets contribute importantly to myocardial reperfusion injury. , 2006, American journal of physiology. Heart and circulatory physiology.

[9]  E. Antman,et al.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. , 2005, JAMA.

[10]  R. Cannon.  Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction , 2005, Nature Clinical Practice Cardiovascular Medicine.

[11]  R. Bolli,et al.  Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy , 2004, Circulation research.

[12]  A. Colombo,et al.  A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[13]  P. Armstrong,et al.  Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial , 2003, Circulation.

[14]  E. Antman,et al.  Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial , 2002, The Lancet.

[15]  R. Gibbons,et al.  The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. , 2002, Journal of the American College of Cardiology.

[16]  P. Boekstegers,et al.  Molecular mechanisms of platelet‐mediated leukocyte recruitment during myocardial reperfusion , 2002, Journal of leukocyte biology.

[17]  J. Harlan,et al.  Leukocyte-endothelial interactions: Clinical trials of anti-adhesion therapy , 2002, Critical care medicine.

[18]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[19]  R. Gibbons,et al.  Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study , 2001, Circulation.

[20]  D. Granger,et al.  Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[21]  J. Pernow,et al.  Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion , 2001, Basic Research in Cardiology.

[22]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[23]  E. Antman,et al.  Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. , 2001, American heart journal.

[24]  P. Boekstegers,et al.  c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen: Implications for Myocardial Reperfusion Injury , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  E. Antman,et al.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. , 2000, Circulation.

[26]  D. Yellon,et al.  Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? , 1999, Trends in cardiovascular medicine.

[27]  P. Gurbel,et al.  Mild Myocardial Stunning Affects Platelet Aggregation and Certain Hemostatic Factors in Swine , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[28]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[29]  A. Kastrati,et al.  Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. , 1998, Circulation.

[30]  A. M. Lefer,et al.  Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. , 1998, Circulation.

[31]  S. Zahler,et al.  Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion. , 1998, Journal of cardiovascular pharmacology.

[32]  S. Zahler,et al.  Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. , 1998, Cardiovascular research.

[33]  L. Becker,et al.  Progression of myocardial necrosis during reperfusion of ischemic myocardium. , 1998, Circulation.

[34]  N. Rao,et al.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  M. Arai,et al.  An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. , 1996, Journal of the American College of Cardiology.

[36]  P. Chiu,et al.  Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  D. Sheridan,et al.  Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. , 1994, Cardiovascular research.

[38]  A. M. Lefer,et al.  Time course of endothelial dysfunction and myocardial injury during coronary arterial occlusion. , 1991, The American journal of physiology.

[39]  T. Hohlfeld,et al.  Stimulation of Prostacyclin Synthesis by Defibrotide: Improved Contractile Rocovery from Myocardial “Stunning” , 1991, Journal of cardiovascular pharmacology.

[40]  R. Califf,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[41]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[42]  P. Armstrong,et al.  Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. , 2007, JAMA.

[43]  K. Messmer,et al.  Platelet-Endothelial Cell Interactions During Ischemia / Reperfusion : The Role of P-Selectin , 1998 .

[44]  R. Jennings,et al.  Development of cell injury in sustained acute ischemia. , 1990, Circulation.

[45]  R. Leiderer,et al.  Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. , 1999, Blood.